| pubmed-article:2894698 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2894698 | lifeskim:mentions | umls-concept:C0036751 | lld:lifeskim |
| pubmed-article:2894698 | lifeskim:mentions | umls-concept:C0006462 | lld:lifeskim |
| pubmed-article:2894698 | lifeskim:mentions | umls-concept:C0040616 | lld:lifeskim |
| pubmed-article:2894698 | lifeskim:mentions | umls-concept:C0050079 | lld:lifeskim |
| pubmed-article:2894698 | lifeskim:mentions | umls-concept:C0681797 | lld:lifeskim |
| pubmed-article:2894698 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:2894698 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:2894698 | lifeskim:mentions | umls-concept:C0086597 | lld:lifeskim |
| pubmed-article:2894698 | lifeskim:mentions | umls-concept:C0123905 | lld:lifeskim |
| pubmed-article:2894698 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:2894698 | pubmed:dateCreated | 1988-4-18 | lld:pubmed |
| pubmed-article:2894698 | pubmed:abstractText | The present study evaluated the role of various neurotransmitter systems in mediating buspirone's blockade of the fear-potentiated startle effect, where acoustic startle amplitude is normally increase in the presence of a light previously paired with a shock. Large lesions of the dorsal and median raphe nuclei or IP injections of the serotonin antagonists cinanserin (10 mg/kg) or cyproheptadine (5 mg/kg) did not alter fear-potentiated startle, nor did these treatments prevent buspirone (5 or 10 mg/kg SC) from blocking fear-potentiated startle. The 5-HT 1A agonist 8-OH-DPAT (2.5-10.0) did not block fear-potentiated startle even at doses that produced a marked "5-HT syndrome". Another 5-HT 1A agonist, ipsapirone (10-20 mg/kg), blocked potentiated startle only at a very high dose (40 mg/kg). p-Chlorophenylalanine and p-chloroamphetamine did not alter fear-potentiated startle. Finally, pretreatment with the benzodiazepine receptor antagonist RO-15-1788 (1 mg/kg); the opiate antagonist naloxone (2 mg/kg) or the alpha 2-adrenergic antagonist yohimbine (5 mg/kg) did not reduce fear-potentiated startle, nor did they prevent buspirone from blocking fear-potentiated startle. Taken together, the data do not support the hypothesis that buspirone's anxiolytic effects are mediated by actions at 5-HT 1A receptors and more generally indicate that serotonergic neurons do not play an important role in fear-potentiated startle. | lld:pubmed |
| pubmed-article:2894698 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2894698 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2894698 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2894698 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2894698 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2894698 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2894698 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2894698 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2894698 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2894698 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2894698 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2894698 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2894698 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2894698 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2894698 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2894698 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2894698 | pubmed:issn | 0033-3158 | lld:pubmed |
| pubmed-article:2894698 | pubmed:author | pubmed-author:DavisMM | lld:pubmed |
| pubmed-article:2894698 | pubmed:author | pubmed-author:KehneJ HJH | lld:pubmed |
| pubmed-article:2894698 | pubmed:author | pubmed-author:CassellaJ VJV | lld:pubmed |
| pubmed-article:2894698 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2894698 | pubmed:volume | 94 | lld:pubmed |
| pubmed-article:2894698 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2894698 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2894698 | pubmed:pagination | 14-20 | lld:pubmed |
| pubmed-article:2894698 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:2894698 | pubmed:meshHeading | pubmed-meshheading:2894698-... | lld:pubmed |
| pubmed-article:2894698 | pubmed:meshHeading | pubmed-meshheading:2894698-... | lld:pubmed |
| pubmed-article:2894698 | pubmed:meshHeading | pubmed-meshheading:2894698-... | lld:pubmed |
| pubmed-article:2894698 | pubmed:meshHeading | pubmed-meshheading:2894698-... | lld:pubmed |
| pubmed-article:2894698 | pubmed:meshHeading | pubmed-meshheading:2894698-... | lld:pubmed |
| pubmed-article:2894698 | pubmed:meshHeading | pubmed-meshheading:2894698-... | lld:pubmed |
| pubmed-article:2894698 | pubmed:meshHeading | pubmed-meshheading:2894698-... | lld:pubmed |
| pubmed-article:2894698 | pubmed:meshHeading | pubmed-meshheading:2894698-... | lld:pubmed |
| pubmed-article:2894698 | pubmed:meshHeading | pubmed-meshheading:2894698-... | lld:pubmed |
| pubmed-article:2894698 | pubmed:meshHeading | pubmed-meshheading:2894698-... | lld:pubmed |
| pubmed-article:2894698 | pubmed:meshHeading | pubmed-meshheading:2894698-... | lld:pubmed |
| pubmed-article:2894698 | pubmed:meshHeading | pubmed-meshheading:2894698-... | lld:pubmed |
| pubmed-article:2894698 | pubmed:meshHeading | pubmed-meshheading:2894698-... | lld:pubmed |
| pubmed-article:2894698 | pubmed:meshHeading | pubmed-meshheading:2894698-... | lld:pubmed |
| pubmed-article:2894698 | pubmed:meshHeading | pubmed-meshheading:2894698-... | lld:pubmed |
| pubmed-article:2894698 | pubmed:meshHeading | pubmed-meshheading:2894698-... | lld:pubmed |
| pubmed-article:2894698 | pubmed:meshHeading | pubmed-meshheading:2894698-... | lld:pubmed |
| pubmed-article:2894698 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:2894698 | pubmed:articleTitle | Serotonin does not mediate anxiolytic effects of buspirone in the fear-potentiated startle paradigm: comparison with 8-OH-DPAT and ipsapirone. | lld:pubmed |
| pubmed-article:2894698 | pubmed:affiliation | Yale University School of Medicine, Ribicoff Research Facilities of the Connecticut Mental Health Center, New Haven 06508. | lld:pubmed |
| pubmed-article:2894698 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2894698 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:2894698 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:2894698 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| pubmed-article:2894698 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2894698 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2894698 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2894698 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2894698 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2894698 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2894698 | lld:pubmed |
